FDA approved Arikayce for Mycobacterium Avium complex
FDA approved Arikayce (amikacin liposomal inhalation suspension) recently for patients with Mycobacterium-avium complex infections, not responding to conventional treatment. Boxed Warning Boxed warning with Arikayce includes hypersensitivity pneumonitis, bronchospasm, hemoptysis and exacerbation of the underlying chronic lung disease. Other side effects include dysphonia, cough, ototoxicity, upper airway irritation, fatigue, nausea, diarrhea and myalgias. Safety and …
FDA approved Arikayce for Mycobacterium Avium complex Read More »